1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases

A compound and a low-level technology applied in the field of 1H-imidazo[4,5-C]quinoline derivatives for the treatment of protein kinase-dependent diseases
CN1882586AInactive Publication Date: 2006-12-20NOVARTIS AG
125 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
NOVARTIS AG
Publication Date
2006-12-20
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the use of imidazoquinoline compounds and salts thereof in the treatment of protein kinase-dependent diseases and in the preparation of pharmaceutical preparations for treating the diseases; imidazoquinoline compounds for the treatment of protein kinase-dependent diseases; Method for treating said diseases, comprising administering imidazoquinolines to warm-blooded animals, especially humans; pharmaceutical preparations comprising imidazoquinolines, especially for the treatment of protein kinase-dependent diseases; novel imidazole and quinolines; and methods of preparing novel imidazoquinolines. Background technique

[0002] Recently, the concept of treating proliferative diseases with drugs specifically designed to act against abnormally active protein kinases has been well established in the treatment of chronic myelogenous leukemia (CML), with the first product now approved for Successful treatment. Clinical studies have shown that t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More